National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Drug Dictionary
Page Options
Print This Page  Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
Contains
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

gemcitabine hydrochloride  Patient Information
The hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms:difluorodeoxycytidine hydrochloride
gemcitabine
US brand name:Gemzar
Abbreviations:dFdC
dFdCyd
Code name:LY-188011
Chemical structure names:
  • 1-(2-oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose hydrochloride
  • 2'-deoxy-2',2'-difluorocytidine hydrochloride
  • 2'deoxy-2',2'-difluorocytidine hydrochloride


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov